TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01129570
Drug: Silybin
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
Study: NCT03455335
Drug: 80 million hMSCs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01041729
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment.
Study: NCT02818491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% in 2 mls
Study: NCT02730208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to TEZ/IVA fixed-dose combination tablet.
Study: NCT02730208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to IVA tablet.
Study: NCT02789332
Drug: PwO
Normalized name: Tilia sapwood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
Study: NCT02789332
Drug: PwCb
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
Study: NCT00626054
Drug: PEG solution in a single dose of 3 liters
Normalized name: PEG-3 cocamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
Study: NCT02310646
Drug: Daivobet® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
Study: NCT01902134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single oral dose (first 8 hours)
Study: NCT01902134
Drug: Dexketoprofen-single dose
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen single oral dose (first 8 hours)
Study: NCT01902134
Drug: Dexketoprofen/Tramadol-single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen/Tramadol oral single dose (first 8 hours)
Study: NCT01902134
Drug: Dexketoprofen-multiple doses
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
Study: NCT01902134
Drug: Dexketoprofen/Tramadol-multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Study: NCT02543086
Drug: KAE609
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug
Study: NCT02379793
Drug: LEO 80185 gel, vehicle, liquid paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
Study: NCT04151342
Drug: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
Study: NCT02812355
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00371007
Drug: Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03073577
Drug: Antiaging Glycopeptide
Normalized name: oligopeptide 104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
Study: NCT04156230
Drug: [18F]GP1 positron emission tomography/computed tomography
Approvals — FDA: no, EMA: no, PMDA: no
Description: A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of \[18F\]GP1.
Study: NCT04749810
Drug: Elizaria®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
Study: NCT03627195
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection
Study: NCT04095390
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg
Study: NCT02601911
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
Study: NCT04564742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
Study: NCT01188954
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 ml/mg
Study: NCT02715479
Drug: BMS955176
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS955176
Study: NCT01400854
Drug: Effentora®
Approvals — FDA: no, EMA: no, PMDA: no
Description: prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
Study: NCT02666534
Drug: methyl-aminolevulinate application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
Study: NCT03313076
Drug: Omega-3 fatty acid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
Study: NCT05102045
Drug: Acetylcholinesterase Inhibitors
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
Study: NCT00742482
Drug: HL 10
Normalized name: benzocaine/benzalk chl 10 %-0.13 % TOPICAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze dried HL 10
Study: NCT04115306
Drug: PMD-026
Normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational Drug
Study: NCT03089554
Drug: Therapeutic Intervention
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Intervention
Study: NCT03634332
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
Study: NCT04006847
Drug: Tyrosine kinase inhibitor
Normalized name: Protein-tyrosine kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
Study: NCT02292433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, breakfast plus lunch, 7 days
Study: NCT01082445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04510220
Drug: [F-18]PBR06
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
Study: NCT00625742
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg by mouth (PO) Daily
Study: NCT00625742
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1200mg/day in three divided doses.
Study: NCT01081262
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04542499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Study: NCT00850161
Drug: Nasulin™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU(2 puffs in each nostril)
Study: NCT03954041
Drug: BIIB093
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03954041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT00382291
Drug: Regular Titration
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
Study: NCT00382291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
Study: NCT00382291
Drug: Slow Titration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
Study: NCT01498419
Drug: Rifafour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
Study: NCT01270841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule 1x daily for 3 months
Study: NCT04551079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-994 placebo-matching tablets.
Study: NCT01623167
Drug: Cohort 2: hATG, CsA, EPAG Day 14 to Month 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
Study: NCT01623167
Drug: Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
Study: NCT01623167
Drug: Extension Cohort
Normalized name: EXTENSION TUBES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
Study: NCT01110499
Drug: AGN-210961 Formulation 1
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210961 Formulation 1 in one eye once daily for 7 days.
Study: NCT01869491
Drug: Matching placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets four times daily
Study: NCT01110499
Drug: AGN-210961 Formulation 2
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210961 Formulation 2 in one eye once daily for 7 days.
Study: NCT01110499
Drug: AGN-210961 Formulation 3
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210961 Formulation 3 in one eye once daily for 7 days.
Study: NCT01110499
Drug: AGN-210961 Formulation 5
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210961 Formulation 5 in one eye once daily for 7 days.
Study: NCT03958565
Drug: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
Normalized name: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Q4 weeks as standard of care
Study: NCT01110499
Drug: AGN-210961 Formulation 6
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210961 Formulation 6 in one eye once daily for 7 days.
Study: NCT01110499
Drug: AGN-210961 Formulation 7
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
Study: NCT00769899
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral, single dose
Study: NCT00769899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for oral, single dose
Study: NCT02544633
Drug: MGCD265
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
Study: NCT01337687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
Study: NCT01224756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
Study: NCT03405337
Drug: FVIII products
Normalized name: factor VIII Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adynovate, Eloctate, Afstyla, Kovaltry
Study: NCT01410539
Drug: OCT guided medical therapy
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCT guided medical therapy. Tailored antiplatelet therapy.
Study: NCT03524937
Drug: MELATONIN (HIGH DOSE)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
Study: NCT03524937
Drug: MELATONIN (LOW DOSE)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
Study: NCT03524937
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
Study: NCT00715169
Drug: MLN1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
Study: NCT02597634
Drug: SST-0225
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
Study: NCT00409188
Drug: Single low dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
Study: NCT00409188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
Study: NCT04410536
Drug: Symptomatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide
Study: NCT04410536
Drug: Bridge therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day
Study: NCT02650505
Drug: LEO 43204
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02650505
Drug: LEO 43204 Vehicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02597634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
Study: NCT01033656
Drug: comparators
Approvals — FDA: no, EMA: no, PMDA: no
Description: po drugs, comparators
Study: NCT00845754
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg IV every6 hours for 4doses
Study: NCT03066154
Drug: androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT according to the standard of care
Study: NCT02684487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
Study: NCT02214498
Drug: Enalapril/hydrochlorothiazide
Normalized name: ENALAPRIL/HYDROCHLOROTHIAZIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
Study: NCT01406925
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream
Study: NCT01406925
Drug: NRL001 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream for single-dose intra-anal application
Study: NCT02316912
Drug: ATX2417
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised double blind parallel group ascending dose assessment
Study: NCT02316912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised double blind parallel group ascending dose assessment
Study: NCT04176887
Drug: Phenytoin Injection
Normalized name: phenytoin Injection
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
Study: NCT01363388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID for 84 days
Study: NCT01363388
Drug: CCX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID for 84 days
Study: NCT03988413
Drug: 400mg
Normalized name: MESNA 400MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 400mg or Placebo 400mg
Study: NCT04378010
Drug: EDP-305 1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04378010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01792284
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03601000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules 5g given three times a day for up to 16 weeks.
Study: NCT03149393
Drug: Qizhi Weitong Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
Study: NCT02537574
Drug: NTX/BUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses
Study: NCT02537574
Drug: NTX/PBO-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses
Study: NCT02537574
Drug: PBO-N/PBO-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses
Study: NCT02663687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo
Study: NCT02663687
Drug: SHP623
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP623
Study: NCT02663687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03580239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
Study: NCT04394182
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/24h, 3 days
Study: NCT04394182
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: prophylactic doses
Study: NCT04394182
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg x 3 boluses
Study: NCT00112697
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03931668
Drug: TPN-672
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of TPN-672 maleate tablet
Study: NCT01880047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00926068
Drug: HO/03/03 10µg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00926068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00403364
Drug: Placebo amoxicillin pantoprazole clarithromycin tinidazole
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02600806
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients are given oral azithromycin when procalcitonin levels are \< 0.5 ng/ml
Study: NCT03757585
Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Treatment with Omega-3 Fatty Acids + Inositol
Study: NCT03757585
Drug: Open-label Treatment with N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Treatment with acetylcysteine